Half-year report · Q2
9273.TEDINET S100V85J
Period2024-07-01 → 2024-12-31
Filed2025-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.3bn | 2024-07-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥22.1bn | 2023-07-01 → 2024-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.4bn | 2023-07-01 → 2023-12-31 | Cons. | Net sales |
| Operating income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Operating income |
| Operating income | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.4bn | 2023-07-01 → 2024-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.9bn | 2023-07-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.6bn | 2023-07-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss |
| Net income | ¥1.6bn | 2023-07-01 → 2023-12-31 | Cons. | Profit loss |
| Total assets | ¥33.6bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥32.0bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥29.6bn | at 2023-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.0bn | at 2024-12-31 | Cons. | Liabilities |
| Total liabilities | ¥7.0bn | at 2024-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥26.6bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥25.1bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥22.0bn | at 2023-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥12.5bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.0bn | at 2024-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥9.8bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.2bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.3bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.0bn | at 2023-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.0bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.8bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.5bn | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.7bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.5bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥644m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥738m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥795m | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥639m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥48.66 | 2024-07-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.14 | 2023-07-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.46 | 2023-07-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 79.1% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.3% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.2% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2024-12-31 | ¥81m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥8.0bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥7.4bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.6bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.4bn |
| —segment total | revenue | 2024-07-01 → 2024-12-31 | ¥12.9bn |
| —segment total | revenue external | 2024-07-01 → 2024-12-31 | ¥12.3bn |
| —segment total | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| —segment total | segment profit | 2024-07-01 → 2024-12-31 | ¥3.0bn |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-12-31 | −¥871m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-12-31 | −¥871m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-12-31 | −¥38m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥7.9bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥7.0bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥871m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1.0bn |
| —segment total | revenue | 2023-07-01 → 2023-12-31 | ¥12.3bn |
| —segment total | revenue external | 2023-07-01 → 2023-12-31 | ¥11.4bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥871m |
| —segment total | segment profit | 2023-07-01 → 2023-12-31 | ¥2.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 494
| Item | Context | Value | Unit |
|---|---|---|---|
| Comprehensive income | Prior1YTDDuration | 1537530000 | JPY |
| Comprehensive income | CurrentYTDDuration | 2053876000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 1537530000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 2053876000 | JPY |
| Income before income taxes | Prior1YTDDuration | 2440109000 | JPY |
| Income before income taxes | CurrentYTDDuration | 3065617000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration | 350895000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration | 338485000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YTDDuration | -13219000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYTDDuration | -13398000 | JPY |
| Increase decrease in provision for directors retirement benefits ope cf | Prior1YTDDuration | 6514000 | JPY |
| Increase decrease in provision for directors retirement benefits ope cf | CurrentYTDDuration | 5863000 | JPY |
| Increase decrease in net defined benefit asset ope cf | Prior1YTDDuration | 8353000 | JPY |
| Increase decrease in net defined benefit asset ope cf | CurrentYTDDuration | 7975000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | 14566000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | -18984000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -1948000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -2210000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 3359000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 6349000 | JPY |
| Compensation income ope cf | Prior1YTDDuration | -640000 | JPY |
| Compensation income ope cf | CurrentYTDDuration | -33892000 | JPY |
| Insurance income ope cf | Prior1YTDDuration | -26533000 | JPY |
| Insurance income ope cf | CurrentYTDDuration | － | JPY |
| Foreign exchange losses gains ope cf | Prior1YTDDuration | 609000 | JPY |
| Foreign exchange losses gains ope cf | CurrentYTDDuration | 9645000 | JPY |
| Loss gain on sales and retirement of noncurrent assets ope cf | Prior1YTDDuration | 0 | JPY |
| Loss gain on sales and retirement of noncurrent assets ope cf | CurrentYTDDuration | 3919000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | -816827000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | -1471847000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -48493000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -232129000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 508016000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | 81497000 | JPY |
| Decrease increase in accounts receivable other ope cf | Prior1YTDDuration | 1646000 | JPY |
| Decrease increase in accounts receivable other ope cf | CurrentYTDDuration | -20019000 | JPY |
| Other net ope cf | Prior1YTDDuration | -208767000 | JPY |
| Other net ope cf | CurrentYTDDuration | -36368000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 2217642000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 1690502000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 1780000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 4451000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -3121000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -6415000 | JPY |
| Proceeds from subsidy ope cf | Prior1YTDDuration | 776000 | JPY |
| Proceeds from subsidy ope cf | CurrentYTDDuration | 300000 | JPY |
| Proceeds from compensation ope cf | Prior1YTDDuration | 570000 | JPY |
| Proceeds from compensation ope cf | CurrentYTDDuration | 33846000 | JPY |
| Proceeds from insurance income ope cf | Prior1YTDDuration | 26533000 | JPY |
| Proceeds from insurance income ope cf | CurrentYTDDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |